nodes	percent_of_prediction	percent_of_DWPC	metapath
Methyldopa—ADRA2A—epilepsy syndrome	0.499	1	CbGaD
Methyldopa—DDC—telencephalic ventricle—epilepsy syndrome	0.0106	0.153	CbGeAlD
Methyldopa—COMT—telencephalic ventricle—epilepsy syndrome	0.00703	0.101	CbGeAlD
Methyldopa—DDC—ganglion—epilepsy syndrome	0.00661	0.0954	CbGeAlD
Methyldopa—DDC—hindbrain—epilepsy syndrome	0.00502	0.0724	CbGeAlD
Methyldopa—COMT—ganglion—epilepsy syndrome	0.00437	0.0631	CbGeAlD
Methyldopa—Metyrosine—TH—epilepsy syndrome	0.00324	0.551	CrCbGaD
Methyldopa—DDC—brainstem—epilepsy syndrome	0.00288	0.0415	CbGeAlD
Methyldopa—DDC—forebrain—epilepsy syndrome	0.00277	0.04	CbGeAlD
Methyldopa—DDC—telencephalon—epilepsy syndrome	0.00255	0.0368	CbGeAlD
Methyldopa—COMT—brainstem—epilepsy syndrome	0.0019	0.0274	CbGeAlD
Methyldopa—COMT—forebrain—epilepsy syndrome	0.00183	0.0265	CbGeAlD
Methyldopa—DDC—midbrain—epilepsy syndrome	0.00183	0.0264	CbGeAlD
Methyldopa—COMT—telencephalon—epilepsy syndrome	0.00169	0.0243	CbGeAlD
Methyldopa—DDC—head—epilepsy syndrome	0.00159	0.0229	CbGeAlD
Methyldopa—DDC—nervous system—epilepsy syndrome	0.00151	0.0217	CbGeAlD
Methyldopa—DDC—central nervous system—epilepsy syndrome	0.00145	0.0209	CbGeAlD
Methyldopa—COMT—medulla oblongata—epilepsy syndrome	0.00133	0.0191	CbGeAlD
Methyldopa—COMT—midbrain—epilepsy syndrome	0.00121	0.0175	CbGeAlD
Methyldopa—COMT—spinal cord—epilepsy syndrome	0.00118	0.0171	CbGeAlD
Methyldopa—DDC—brain—epilepsy syndrome	0.00115	0.0166	CbGeAlD
Methyldopa—COMT—head—epilepsy syndrome	0.00105	0.0152	CbGeAlD
Methyldopa—COMT—nervous system—epilepsy syndrome	0.000996	0.0144	CbGeAlD
Methyldopa—COMT—central nervous system—epilepsy syndrome	0.000959	0.0138	CbGeAlD
Methyldopa—COMT—cerebellum—epilepsy syndrome	0.000937	0.0135	CbGeAlD
Methyldopa—ADRA2A—forebrain—epilepsy syndrome	0.000934	0.0135	CbGeAlD
Methyldopa—ADRA2A—telencephalon—epilepsy syndrome	0.000859	0.0124	CbGeAlD
Methyldopa—COMT—brain—epilepsy syndrome	0.000761	0.011	CbGeAlD
Methyldopa—ADRA2A—medulla oblongata—epilepsy syndrome	0.000675	0.00974	CbGeAlD
Methyldopa—ADRA2A—midbrain—epilepsy syndrome	0.000617	0.0089	CbGeAlD
Methyldopa—ADRA2A—spinal cord—epilepsy syndrome	0.000602	0.00868	CbGeAlD
Methyldopa—ADRA2A—head—epilepsy syndrome	0.000535	0.00772	CbGeAlD
Methyldopa—ADRA2A—nervous system—epilepsy syndrome	0.000507	0.00732	CbGeAlD
Methyldopa—ADRA2A—central nervous system—epilepsy syndrome	0.000488	0.00704	CbGeAlD
Methyldopa—ADRA2A—cerebellum—epilepsy syndrome	0.000477	0.00689	CbGeAlD
Methyldopa—Levonordefrin—ADRA2A—epilepsy syndrome	0.000413	0.0704	CrCbGaD
Methyldopa—ADRA2A—brain—epilepsy syndrome	0.000388	0.00559	CbGeAlD
Methyldopa—Droxidopa—ADRA2A—epilepsy syndrome	0.000291	0.0496	CrCbGaD
Methyldopa—Dopamine—HTR7—epilepsy syndrome	0.000266	0.0452	CrCbGaD
Methyldopa—Norepinephrine—ADRA2A—epilepsy syndrome	0.000245	0.0417	CrCbGaD
Methyldopa—Epinephrine—ADRA2A—epilepsy syndrome	0.000222	0.0379	CrCbGaD
Methyldopa—Aminosalicylic Acid—PTGS2—epilepsy syndrome	0.000221	0.0377	CrCbGaD
Methyldopa—Epinephrine—TNF—epilepsy syndrome	0.000211	0.0359	CrCbGaD
Methyldopa—Gastrointestinal disorder—Clonazepam—epilepsy syndrome	0.000189	0.000697	CcSEcCtD
Methyldopa—Cardiac disorder—Pregabalin—epilepsy syndrome	0.000188	0.000695	CcSEcCtD
Methyldopa—Asthenia—Midazolam—epilepsy syndrome	0.000188	0.000694	CcSEcCtD
Methyldopa—Gastrointestinal disorder—Phenytoin—epilepsy syndrome	0.000187	0.000693	CcSEcCtD
Methyldopa—Constipation—Clonazepam—epilepsy syndrome	0.000187	0.000691	CcSEcCtD
Methyldopa—Gastrointestinal disorder—Oxcarbazepine—epilepsy syndrome	0.000186	0.000689	CcSEcCtD
Methyldopa—Paraesthesia—Carbamazepine—epilepsy syndrome	0.000186	0.000688	CcSEcCtD
Methyldopa—Hepatitis—Gabapentin—epilepsy syndrome	0.000186	0.000686	CcSEcCtD
Methyldopa—Constipation—Phenytoin—epilepsy syndrome	0.000186	0.000686	CcSEcCtD
Methyldopa—Asthenia—Levetiracetam—epilepsy syndrome	0.000185	0.000685	CcSEcCtD
Methyldopa—Pancytopenia—Topiramate—epilepsy syndrome	0.000185	0.000685	CcSEcCtD
Methyldopa—Constipation—Oxcarbazepine—epilepsy syndrome	0.000185	0.000682	CcSEcCtD
Methyldopa—Angiopathy—Pregabalin—epilepsy syndrome	0.000184	0.000679	CcSEcCtD
Methyldopa—Body temperature increased—Felbamate—epilepsy syndrome	0.000183	0.000677	CcSEcCtD
Methyldopa—Vomiting—Acetazolamide—epilepsy syndrome	0.000183	0.000677	CcSEcCtD
Methyldopa—Diarrhoea—Propofol—epilepsy syndrome	0.000183	0.000676	CcSEcCtD
Methyldopa—Mediastinal disorder—Pregabalin—epilepsy syndrome	0.000182	0.000675	CcSEcCtD
Methyldopa—Connective tissue disorder—Gabapentin—epilepsy syndrome	0.000182	0.000674	CcSEcCtD
Methyldopa—Musculoskeletal discomfort—Lamotrigine—epilepsy syndrome	0.000182	0.000674	CcSEcCtD
Methyldopa—Headache—Acetazolamide—epilepsy syndrome	0.00018	0.000667	CcSEcCtD
Methyldopa—Paraesthesia—Lamotrigine—epilepsy syndrome	0.00018	0.000665	CcSEcCtD
Methyldopa—Erectile dysfunction—Topiramate—epilepsy syndrome	0.00018	0.000664	CcSEcCtD
Methyldopa—Body temperature increased—Zonisamide—epilepsy syndrome	0.000179	0.000663	CcSEcCtD
Methyldopa—Hypersensitivity—Vigabatrin—epilepsy syndrome	0.000179	0.000662	CcSEcCtD
Methyldopa—Asthenia—Fosphenytoin—epilepsy syndrome	0.000179	0.000661	CcSEcCtD
Methyldopa—Gastrointestinal disorder—Carbamazepine—epilepsy syndrome	0.000179	0.000661	CcSEcCtD
Methyldopa—Weight increased—Topiramate—epilepsy syndrome	0.000178	0.000656	CcSEcCtD
Methyldopa—Mental disorder—Pregabalin—epilepsy syndrome	0.000177	0.000656	CcSEcCtD
Methyldopa—Constipation—Carbamazepine—epilepsy syndrome	0.000177	0.000655	CcSEcCtD
Methyldopa—Dizziness—Propofol—epilepsy syndrome	0.000177	0.000654	CcSEcCtD
Methyldopa—Diarrhoea—Levetiracetam—epilepsy syndrome	0.000177	0.000654	CcSEcCtD
Methyldopa—Hypersensitivity—Diazepam—epilepsy syndrome	0.000176	0.000652	CcSEcCtD
Methyldopa—Leukopenia—Valproic Acid—epilepsy syndrome	0.000175	0.000645	CcSEcCtD
Methyldopa—Asthenia—Vigabatrin—epilepsy syndrome	0.000174	0.000645	CcSEcCtD
Methyldopa—Infestation NOS—Topiramate—epilepsy syndrome	0.000174	0.000643	CcSEcCtD
Methyldopa—Infestation—Topiramate—epilepsy syndrome	0.000174	0.000643	CcSEcCtD
Methyldopa—Mesalazine—PTGS2—epilepsy syndrome	0.000174	0.0296	CrCbGaD
Methyldopa—Dopamine—SLC6A4—epilepsy syndrome	0.000174	0.0296	CrCbGaD
Methyldopa—Flatulence—Pregabalin—epilepsy syndrome	0.000174	0.000642	CcSEcCtD
Methyldopa—Dizziness—Midazolam—epilepsy syndrome	0.000173	0.00064	CcSEcCtD
Methyldopa—Gastrointestinal disorder—Lamotrigine—epilepsy syndrome	0.000173	0.000639	CcSEcCtD
Methyldopa—Body temperature increased—Clonazepam—epilepsy syndrome	0.000173	0.000639	CcSEcCtD
Methyldopa—Cardiac disorder—Gabapentin—epilepsy syndrome	0.000172	0.000637	CcSEcCtD
Methyldopa—Asthenia—Diazepam—epilepsy syndrome	0.000172	0.000635	CcSEcCtD
Methyldopa—Body temperature increased—Phenytoin—epilepsy syndrome	0.000172	0.000634	CcSEcCtD
Methyldopa—Constipation—Lamotrigine—epilepsy syndrome	0.000171	0.000633	CcSEcCtD
Methyldopa—Nausea—Acetazolamide—epilepsy syndrome	0.000171	0.000632	CcSEcCtD
Methyldopa—Dizziness—Levetiracetam—epilepsy syndrome	0.000171	0.000632	CcSEcCtD
Methyldopa—Body temperature increased—Oxcarbazepine—epilepsy syndrome	0.000171	0.000631	CcSEcCtD
Methyldopa—Diarrhoea—Fosphenytoin—epilepsy syndrome	0.000171	0.000631	CcSEcCtD
Methyldopa—Vomiting—Propofol—epilepsy syndrome	0.00017	0.000629	CcSEcCtD
Methyldopa—Rash—Propofol—epilepsy syndrome	0.000169	0.000623	CcSEcCtD
Methyldopa—Dermatitis—Propofol—epilepsy syndrome	0.000168	0.000623	CcSEcCtD
Methyldopa—Headache—Propofol—epilepsy syndrome	0.000168	0.000619	CcSEcCtD
Methyldopa—Mediastinal disorder—Gabapentin—epilepsy syndrome	0.000167	0.000619	CcSEcCtD
Methyldopa—Hypersensitivity—Zonisamide—epilepsy syndrome	0.000167	0.000617	CcSEcCtD
Methyldopa—Vomiting—Midazolam—epilepsy syndrome	0.000166	0.000615	CcSEcCtD
Methyldopa—Diarrhoea—Vigabatrin—epilepsy syndrome	0.000166	0.000615	CcSEcCtD
Methyldopa—Asthenia—Felbamate—epilepsy syndrome	0.000166	0.000614	CcSEcCtD
Methyldopa—Arthralgia—Valproic Acid—epilepsy syndrome	0.000166	0.000614	CcSEcCtD
Methyldopa—Myalgia—Valproic Acid—epilepsy syndrome	0.000166	0.000614	CcSEcCtD
Methyldopa—Rash—Midazolam—epilepsy syndrome	0.000165	0.00061	CcSEcCtD
Methyldopa—Dizziness—Fosphenytoin—epilepsy syndrome	0.000165	0.00061	CcSEcCtD
Methyldopa—Unspecified disorder of skin and subcutaneous tissue—Valproic Acid—epilepsy syndrome	0.000165	0.000609	CcSEcCtD
Methyldopa—Dermatitis—Midazolam—epilepsy syndrome	0.000165	0.000609	CcSEcCtD
Methyldopa—Dopamine—CYP2C19—epilepsy syndrome	0.000165	0.0281	CrCbGaD
Methyldopa—Vomiting—Levetiracetam—epilepsy syndrome	0.000164	0.000607	CcSEcCtD
Methyldopa—Headache—Midazolam—epilepsy syndrome	0.000164	0.000606	CcSEcCtD
Methyldopa—Body temperature increased—Carbamazepine—epilepsy syndrome	0.000164	0.000605	CcSEcCtD
Methyldopa—Diarrhoea—Diazepam—epilepsy syndrome	0.000164	0.000605	CcSEcCtD
Methyldopa—Rash—Levetiracetam—epilepsy syndrome	0.000163	0.000602	CcSEcCtD
Methyldopa—Dermatitis—Levetiracetam—epilepsy syndrome	0.000163	0.000602	CcSEcCtD
Methyldopa—Asthenia—Zonisamide—epilepsy syndrome	0.000163	0.000601	CcSEcCtD
Methyldopa—Mental disorder—Gabapentin—epilepsy syndrome	0.000163	0.000601	CcSEcCtD
Methyldopa—Agranulocytosis—Topiramate—epilepsy syndrome	0.000162	0.0006	CcSEcCtD
Methyldopa—Headache—Levetiracetam—epilepsy syndrome	0.000162	0.000598	CcSEcCtD
Methyldopa—Hypersensitivity—Clonazepam—epilepsy syndrome	0.000161	0.000595	CcSEcCtD
Methyldopa—Dizziness—Vigabatrin—epilepsy syndrome	0.000161	0.000594	CcSEcCtD
Methyldopa—Hypersensitivity—Phenytoin—epilepsy syndrome	0.00016	0.000591	CcSEcCtD
Methyldopa—Flatulence—Gabapentin—epilepsy syndrome	0.000159	0.000589	CcSEcCtD
Methyldopa—Oedema—Valproic Acid—epilepsy syndrome	0.000159	0.000588	CcSEcCtD
Methyldopa—Hypersensitivity—Oxcarbazepine—epilepsy syndrome	0.000159	0.000588	CcSEcCtD
Methyldopa—Bradycardia—Topiramate—epilepsy syndrome	0.000159	0.000588	CcSEcCtD
Methyldopa—Nausea—Propofol—epilepsy syndrome	0.000159	0.000587	CcSEcCtD
Methyldopa—Vomiting—Fosphenytoin—epilepsy syndrome	0.000159	0.000586	CcSEcCtD
Methyldopa—Diarrhoea—Felbamate—epilepsy syndrome	0.000158	0.000586	CcSEcCtD
Methyldopa—Body temperature increased—Lamotrigine—epilepsy syndrome	0.000158	0.000585	CcSEcCtD
Methyldopa—Dizziness—Diazepam—epilepsy syndrome	0.000158	0.000585	CcSEcCtD
Methyldopa—Infection—Valproic Acid—epilepsy syndrome	0.000158	0.000584	CcSEcCtD
Methyldopa—Leukopenia—Pregabalin—epilepsy syndrome	0.000158	0.000583	CcSEcCtD
Methyldopa—Rash—Fosphenytoin—epilepsy syndrome	0.000157	0.000581	CcSEcCtD
Methyldopa—Dermatitis—Fosphenytoin—epilepsy syndrome	0.000157	0.000581	CcSEcCtD
Methyldopa—Asthenia—Clonazepam—epilepsy syndrome	0.000157	0.00058	CcSEcCtD
Methyldopa—Headache—Fosphenytoin—epilepsy syndrome	0.000156	0.000578	CcSEcCtD
Methyldopa—Hepatitis—Topiramate—epilepsy syndrome	0.000156	0.000577	CcSEcCtD
Methyldopa—Nervous system disorder—Valproic Acid—epilepsy syndrome	0.000156	0.000577	CcSEcCtD
Methyldopa—Thrombocytopenia—Valproic Acid—epilepsy syndrome	0.000156	0.000576	CcSEcCtD
Methyldopa—Asthenia—Phenytoin—epilepsy syndrome	0.000156	0.000576	CcSEcCtD
Methyldopa—Nausea—Midazolam—epilepsy syndrome	0.000155	0.000575	CcSEcCtD
Methyldopa—Diarrhoea—Zonisamide—epilepsy syndrome	0.000155	0.000573	CcSEcCtD
Methyldopa—Asthenia—Oxcarbazepine—epilepsy syndrome	0.000155	0.000573	CcSEcCtD
Methyldopa—Vomiting—Vigabatrin—epilepsy syndrome	0.000155	0.000571	CcSEcCtD
Methyldopa—Skin disorder—Valproic Acid—epilepsy syndrome	0.000155	0.000571	CcSEcCtD
Methyldopa—Connective tissue disorder—Topiramate—epilepsy syndrome	0.000153	0.000567	CcSEcCtD
Methyldopa—Nausea—Levetiracetam—epilepsy syndrome	0.000153	0.000567	CcSEcCtD
Methyldopa—Rash—Vigabatrin—epilepsy syndrome	0.000153	0.000567	CcSEcCtD
Methyldopa—Dizziness—Felbamate—epilepsy syndrome	0.000153	0.000566	CcSEcCtD
Methyldopa—Dermatitis—Vigabatrin—epilepsy syndrome	0.000153	0.000566	CcSEcCtD
Methyldopa—Hypersensitivity—Carbamazepine—epilepsy syndrome	0.000153	0.000564	CcSEcCtD
Methyldopa—Headache—Vigabatrin—epilepsy syndrome	0.000152	0.000563	CcSEcCtD
Methyldopa—Vomiting—Diazepam—epilepsy syndrome	0.000152	0.000562	CcSEcCtD
Methyldopa—Rash—Diazepam—epilepsy syndrome	0.000151	0.000558	CcSEcCtD
Methyldopa—Dermatitis—Diazepam—epilepsy syndrome	0.000151	0.000557	CcSEcCtD
Methyldopa—Myalgia—Pregabalin—epilepsy syndrome	0.00015	0.000555	CcSEcCtD
Methyldopa—Arthralgia—Pregabalin—epilepsy syndrome	0.00015	0.000555	CcSEcCtD
Methyldopa—Dizziness—Zonisamide—epilepsy syndrome	0.00015	0.000554	CcSEcCtD
Methyldopa—Headache—Diazepam—epilepsy syndrome	0.00015	0.000554	CcSEcCtD
Methyldopa—Diarrhoea—Clonazepam—epilepsy syndrome	0.00015	0.000553	CcSEcCtD
Methyldopa—Unspecified disorder of skin and subcutaneous tissue—Pregabalin—epilepsy syndrome	0.000149	0.000551	CcSEcCtD
Methyldopa—Asthenia—Carbamazepine—epilepsy syndrome	0.000149	0.000549	CcSEcCtD
Methyldopa—Diarrhoea—Phenytoin—epilepsy syndrome	0.000149	0.000549	CcSEcCtD
Methyldopa—Nausea—Fosphenytoin—epilepsy syndrome	0.000148	0.000548	CcSEcCtD
Methyldopa—Diarrhoea—Oxcarbazepine—epilepsy syndrome	0.000148	0.000546	CcSEcCtD
Methyldopa—Hypersensitivity—Lamotrigine—epilepsy syndrome	0.000148	0.000545	CcSEcCtD
Methyldopa—Vomiting—Felbamate—epilepsy syndrome	0.000147	0.000544	CcSEcCtD
Methyldopa—Rash—Felbamate—epilepsy syndrome	0.000146	0.00054	CcSEcCtD
Methyldopa—Dermatitis—Felbamate—epilepsy syndrome	0.000146	0.000539	CcSEcCtD
Methyldopa—Headache—Felbamate—epilepsy syndrome	0.000145	0.000536	CcSEcCtD
Methyldopa—Musculoskeletal discomfort—Valproic Acid—epilepsy syndrome	0.000145	0.000536	CcSEcCtD
Methyldopa—Cardiac disorder—Topiramate—epilepsy syndrome	0.000145	0.000536	CcSEcCtD
Methyldopa—Leukopenia—Gabapentin—epilepsy syndrome	0.000145	0.000535	CcSEcCtD
Methyldopa—Dizziness—Clonazepam—epilepsy syndrome	0.000144	0.000534	CcSEcCtD
Methyldopa—Nausea—Vigabatrin—epilepsy syndrome	0.000144	0.000534	CcSEcCtD
Methyldopa—Vomiting—Zonisamide—epilepsy syndrome	0.000144	0.000533	CcSEcCtD
Methyldopa—Oedema—Pregabalin—epilepsy syndrome	0.000144	0.000532	CcSEcCtD
Methyldopa—Asthenia—Lamotrigine—epilepsy syndrome	0.000144	0.000531	CcSEcCtD
Methyldopa—Dizziness—Phenytoin—epilepsy syndrome	0.000144	0.000531	CcSEcCtD
Methyldopa—Rash—Zonisamide—epilepsy syndrome	0.000143	0.000528	CcSEcCtD
Methyldopa—Infection—Pregabalin—epilepsy syndrome	0.000143	0.000528	CcSEcCtD
Methyldopa—Paraesthesia—Valproic Acid—epilepsy syndrome	0.000143	0.000528	CcSEcCtD
Methyldopa—Dermatitis—Zonisamide—epilepsy syndrome	0.000143	0.000528	CcSEcCtD
Methyldopa—Dizziness—Oxcarbazepine—epilepsy syndrome	0.000143	0.000528	CcSEcCtD
Methyldopa—Nausea—Diazepam—epilepsy syndrome	0.000142	0.000525	CcSEcCtD
Methyldopa—Headache—Zonisamide—epilepsy syndrome	0.000142	0.000525	CcSEcCtD
Methyldopa—Diarrhoea—Carbamazepine—epilepsy syndrome	0.000142	0.000524	CcSEcCtD
Methyldopa—Angiopathy—Topiramate—epilepsy syndrome	0.000142	0.000524	CcSEcCtD
Methyldopa—Nervous system disorder—Pregabalin—epilepsy syndrome	0.000141	0.000521	CcSEcCtD
Methyldopa—Thrombocytopenia—Pregabalin—epilepsy syndrome	0.000141	0.000521	CcSEcCtD
Methyldopa—Mediastinal disorder—Topiramate—epilepsy syndrome	0.000141	0.00052	CcSEcCtD
Methyldopa—Skin disorder—Pregabalin—epilepsy syndrome	0.00014	0.000516	CcSEcCtD
Methyldopa—Vomiting—Clonazepam—epilepsy syndrome	0.000139	0.000514	CcSEcCtD
Methyldopa—Vomiting—Phenytoin—epilepsy syndrome	0.000138	0.00051	CcSEcCtD
Methyldopa—Rash—Clonazepam—epilepsy syndrome	0.000138	0.000509	CcSEcCtD
Methyldopa—Dermatitis—Clonazepam—epilepsy syndrome	0.000138	0.000509	CcSEcCtD
Methyldopa—Arthralgia—Gabapentin—epilepsy syndrome	0.000138	0.000509	CcSEcCtD
Methyldopa—Myalgia—Gabapentin—epilepsy syndrome	0.000138	0.000509	CcSEcCtD
Methyldopa—Nausea—Felbamate—epilepsy syndrome	0.000138	0.000509	CcSEcCtD
Methyldopa—Gastrointestinal disorder—Valproic Acid—epilepsy syndrome	0.000137	0.000508	CcSEcCtD
Methyldopa—Vomiting—Oxcarbazepine—epilepsy syndrome	0.000137	0.000507	CcSEcCtD
Methyldopa—Dizziness—Carbamazepine—epilepsy syndrome	0.000137	0.000506	CcSEcCtD
Methyldopa—Diarrhoea—Lamotrigine—epilepsy syndrome	0.000137	0.000506	CcSEcCtD
Methyldopa—Headache—Clonazepam—epilepsy syndrome	0.000137	0.000506	CcSEcCtD
Methyldopa—Rash—Phenytoin—epilepsy syndrome	0.000137	0.000506	CcSEcCtD
Methyldopa—Mental disorder—Topiramate—epilepsy syndrome	0.000137	0.000506	CcSEcCtD
Methyldopa—Dermatitis—Phenytoin—epilepsy syndrome	0.000137	0.000505	CcSEcCtD
Methyldopa—Unspecified disorder of skin and subcutaneous tissue—Gabapentin—epilepsy syndrome	0.000137	0.000505	CcSEcCtD
Methyldopa—Rash—Oxcarbazepine—epilepsy syndrome	0.000136	0.000503	CcSEcCtD
Methyldopa—Constipation—Valproic Acid—epilepsy syndrome	0.000136	0.000503	CcSEcCtD
Methyldopa—Dermatitis—Oxcarbazepine—epilepsy syndrome	0.000136	0.000503	CcSEcCtD
Methyldopa—Headache—Phenytoin—epilepsy syndrome	0.000136	0.000503	CcSEcCtD
Methyldopa—Headache—Oxcarbazepine—epilepsy syndrome	0.000135	0.0005	CcSEcCtD
Methyldopa—Nausea—Zonisamide—epilepsy syndrome	0.000135	0.000498	CcSEcCtD
Methyldopa—Flatulence—Topiramate—epilepsy syndrome	0.000134	0.000495	CcSEcCtD
Methyldopa—Dizziness—Lamotrigine—epilepsy syndrome	0.000132	0.000489	CcSEcCtD
Methyldopa—Oedema—Gabapentin—epilepsy syndrome	0.000132	0.000488	CcSEcCtD
Methyldopa—Vomiting—Carbamazepine—epilepsy syndrome	0.000132	0.000487	CcSEcCtD
Methyldopa—L-DOPA—CYP2D6—epilepsy syndrome	0.000131	0.0224	CrCbGaD
Methyldopa—Musculoskeletal discomfort—Pregabalin—epilepsy syndrome	0.000131	0.000484	CcSEcCtD
Methyldopa—Infection—Gabapentin—epilepsy syndrome	0.000131	0.000484	CcSEcCtD
Methyldopa—Rash—Carbamazepine—epilepsy syndrome	0.000131	0.000483	CcSEcCtD
Methyldopa—Dermatitis—Carbamazepine—epilepsy syndrome	0.000131	0.000482	CcSEcCtD
Methyldopa—Nausea—Clonazepam—epilepsy syndrome	0.00013	0.00048	CcSEcCtD
Methyldopa—Headache—Carbamazepine—epilepsy syndrome	0.00013	0.00048	CcSEcCtD
Methyldopa—Nervous system disorder—Gabapentin—epilepsy syndrome	0.000129	0.000478	CcSEcCtD
Methyldopa—Paraesthesia—Pregabalin—epilepsy syndrome	0.000129	0.000477	CcSEcCtD
Methyldopa—Thrombocytopenia—Gabapentin—epilepsy syndrome	0.000129	0.000477	CcSEcCtD
Methyldopa—Nausea—Phenytoin—epilepsy syndrome	0.000129	0.000477	CcSEcCtD
Methyldopa—Nausea—Oxcarbazepine—epilepsy syndrome	0.000128	0.000474	CcSEcCtD
Methyldopa—Skin disorder—Gabapentin—epilepsy syndrome	0.000128	0.000474	CcSEcCtD
Methyldopa—Vomiting—Lamotrigine—epilepsy syndrome	0.000127	0.000471	CcSEcCtD
Methyldopa—Rash—Lamotrigine—epilepsy syndrome	0.000126	0.000467	CcSEcCtD
Methyldopa—Dermatitis—Lamotrigine—epilepsy syndrome	0.000126	0.000466	CcSEcCtD
Methyldopa—Body temperature increased—Valproic Acid—epilepsy syndrome	0.000126	0.000465	CcSEcCtD
Methyldopa—Headache—Lamotrigine—epilepsy syndrome	0.000125	0.000464	CcSEcCtD
Methyldopa—Gastrointestinal disorder—Pregabalin—epilepsy syndrome	0.000124	0.000459	CcSEcCtD
Methyldopa—Nausea—Carbamazepine—epilepsy syndrome	0.000123	0.000455	CcSEcCtD
Methyldopa—Constipation—Pregabalin—epilepsy syndrome	0.000123	0.000455	CcSEcCtD
Methyldopa—Dopamine—CYP2D6—epilepsy syndrome	0.000122	0.0208	CrCbGaD
Methyldopa—Leukopenia—Topiramate—epilepsy syndrome	0.000122	0.00045	CcSEcCtD
Methyldopa—Musculoskeletal discomfort—Gabapentin—epilepsy syndrome	0.00012	0.000444	CcSEcCtD
Methyldopa—Nausea—Lamotrigine—epilepsy syndrome	0.000119	0.00044	CcSEcCtD
Methyldopa—Paraesthesia—Gabapentin—epilepsy syndrome	0.000118	0.000438	CcSEcCtD
Methyldopa—Hypersensitivity—Valproic Acid—epilepsy syndrome	0.000117	0.000433	CcSEcCtD
Methyldopa—Arthralgia—Topiramate—epilepsy syndrome	0.000116	0.000428	CcSEcCtD
Methyldopa—Myalgia—Topiramate—epilepsy syndrome	0.000116	0.000428	CcSEcCtD
Methyldopa—Unspecified disorder of skin and subcutaneous tissue—Topiramate—epilepsy syndrome	0.000115	0.000425	CcSEcCtD
Methyldopa—Asthenia—Valproic Acid—epilepsy syndrome	0.000114	0.000422	CcSEcCtD
Methyldopa—Gastrointestinal disorder—Gabapentin—epilepsy syndrome	0.000114	0.000421	CcSEcCtD
Methyldopa—Body temperature increased—Pregabalin—epilepsy syndrome	0.000114	0.00042	CcSEcCtD
Methyldopa—Constipation—Gabapentin—epilepsy syndrome	0.000113	0.000417	CcSEcCtD
Methyldopa—Oedema—Topiramate—epilepsy syndrome	0.000111	0.00041	CcSEcCtD
Methyldopa—Infection—Topiramate—epilepsy syndrome	0.00011	0.000408	CcSEcCtD
Methyldopa—Diarrhoea—Valproic Acid—epilepsy syndrome	0.000109	0.000402	CcSEcCtD
Methyldopa—Nervous system disorder—Topiramate—epilepsy syndrome	0.000109	0.000402	CcSEcCtD
Methyldopa—Thrombocytopenia—Topiramate—epilepsy syndrome	0.000109	0.000402	CcSEcCtD
Methyldopa—Skin disorder—Topiramate—epilepsy syndrome	0.000108	0.000398	CcSEcCtD
Methyldopa—Hypersensitivity—Pregabalin—epilepsy syndrome	0.000106	0.000392	CcSEcCtD
Methyldopa—Dizziness—Valproic Acid—epilepsy syndrome	0.000105	0.000389	CcSEcCtD
Methyldopa—Body temperature increased—Gabapentin—epilepsy syndrome	0.000104	0.000385	CcSEcCtD
Methyldopa—Asthenia—Pregabalin—epilepsy syndrome	0.000103	0.000381	CcSEcCtD
Methyldopa—Vomiting—Valproic Acid—epilepsy syndrome	0.000101	0.000374	CcSEcCtD
Methyldopa—Musculoskeletal discomfort—Topiramate—epilepsy syndrome	0.000101	0.000374	CcSEcCtD
Methyldopa—Rash—Valproic Acid—epilepsy syndrome	0.0001	0.000371	CcSEcCtD
Methyldopa—Dermatitis—Valproic Acid—epilepsy syndrome	0.0001	0.00037	CcSEcCtD
Methyldopa—Headache—Valproic Acid—epilepsy syndrome	9.97e-05	0.000368	CcSEcCtD
Methyldopa—Paraesthesia—Topiramate—epilepsy syndrome	9.96e-05	0.000368	CcSEcCtD
Methyldopa—Diarrhoea—Pregabalin—epilepsy syndrome	9.84e-05	0.000364	CcSEcCtD
Methyldopa—Hypersensitivity—Gabapentin—epilepsy syndrome	9.72e-05	0.000359	CcSEcCtD
Methyldopa—Gastrointestinal disorder—Topiramate—epilepsy syndrome	9.58e-05	0.000354	CcSEcCtD
Methyldopa—Dizziness—Pregabalin—epilepsy syndrome	9.51e-05	0.000352	CcSEcCtD
Methyldopa—Constipation—Topiramate—epilepsy syndrome	9.49e-05	0.000351	CcSEcCtD
Methyldopa—Asthenia—Gabapentin—epilepsy syndrome	9.46e-05	0.00035	CcSEcCtD
Methyldopa—Nausea—Valproic Acid—epilepsy syndrome	9.45e-05	0.000349	CcSEcCtD
Methyldopa—Vomiting—Pregabalin—epilepsy syndrome	9.15e-05	0.000338	CcSEcCtD
Methyldopa—Rash—Pregabalin—epilepsy syndrome	9.07e-05	0.000335	CcSEcCtD
Methyldopa—Dermatitis—Pregabalin—epilepsy syndrome	9.06e-05	0.000335	CcSEcCtD
Methyldopa—Diarrhoea—Gabapentin—epilepsy syndrome	9.02e-05	0.000334	CcSEcCtD
Methyldopa—Headache—Pregabalin—epilepsy syndrome	9.01e-05	0.000333	CcSEcCtD
Methyldopa—Body temperature increased—Topiramate—epilepsy syndrome	8.77e-05	0.000324	CcSEcCtD
Methyldopa—Dizziness—Gabapentin—epilepsy syndrome	8.72e-05	0.000322	CcSEcCtD
Methyldopa—Nausea—Pregabalin—epilepsy syndrome	8.54e-05	0.000316	CcSEcCtD
Methyldopa—Vomiting—Gabapentin—epilepsy syndrome	8.39e-05	0.00031	CcSEcCtD
Methyldopa—Rash—Gabapentin—epilepsy syndrome	8.32e-05	0.000307	CcSEcCtD
Methyldopa—Dermatitis—Gabapentin—epilepsy syndrome	8.31e-05	0.000307	CcSEcCtD
Methyldopa—Headache—Gabapentin—epilepsy syndrome	8.26e-05	0.000305	CcSEcCtD
Methyldopa—Hypersensitivity—Topiramate—epilepsy syndrome	8.18e-05	0.000302	CcSEcCtD
Methyldopa—Asthenia—Topiramate—epilepsy syndrome	7.96e-05	0.000294	CcSEcCtD
Methyldopa—Nausea—Gabapentin—epilepsy syndrome	7.83e-05	0.00029	CcSEcCtD
Methyldopa—Diarrhoea—Topiramate—epilepsy syndrome	7.59e-05	0.000281	CcSEcCtD
Methyldopa—Dizziness—Topiramate—epilepsy syndrome	7.34e-05	0.000271	CcSEcCtD
Methyldopa—Vomiting—Topiramate—epilepsy syndrome	7.06e-05	0.000261	CcSEcCtD
Methyldopa—Rash—Topiramate—epilepsy syndrome	7e-05	0.000259	CcSEcCtD
Methyldopa—Dermatitis—Topiramate—epilepsy syndrome	6.99e-05	0.000258	CcSEcCtD
Methyldopa—Headache—Topiramate—epilepsy syndrome	6.95e-05	0.000257	CcSEcCtD
Methyldopa—Nausea—Topiramate—epilepsy syndrome	6.59e-05	0.000244	CcSEcCtD
Methyldopa—ADRA2A—Metabolism—ATIC—epilepsy syndrome	3.29e-05	0.000213	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—PLAT—epilepsy syndrome	3.29e-05	0.000212	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—GRM8—epilepsy syndrome	3.29e-05	0.000212	CbGpPWpGaD
Methyldopa—COMT—Metabolism—SLC2A1—epilepsy syndrome	3.2e-05	0.000206	CbGpPWpGaD
Methyldopa—ADRA2A—Class A/1 (Rhodopsin-like receptors)—CCR5—epilepsy syndrome	3.19e-05	0.000206	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—ACKR4—epilepsy syndrome	3.18e-05	0.000205	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—HSD17B4—epilepsy syndrome	3.17e-05	0.000205	CbGpPWpGaD
Methyldopa—COMT—Metabolism—PLCB1—epilepsy syndrome	3.17e-05	0.000204	CbGpPWpGaD
Methyldopa—COMT—Metabolism—TH—epilepsy syndrome	3.15e-05	0.000204	CbGpPWpGaD
Methyldopa—ADRA2A—G alpha (i) signalling events—POMC—epilepsy syndrome	3.14e-05	0.000203	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—OPRD1—epilepsy syndrome	3.13e-05	0.000202	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—GNAO1—epilepsy syndrome	3.13e-05	0.000202	CbGpPWpGaD
Methyldopa—ADRA2A—Class A/1 (Rhodopsin-like receptors)—HTR2A—epilepsy syndrome	3.12e-05	0.000202	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—GAL—epilepsy syndrome	3.11e-05	0.000201	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—NOS1—epilepsy syndrome	3.09e-05	0.000199	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—CHRM3—epilepsy syndrome	3.08e-05	0.000199	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—GRM5—epilepsy syndrome	3.08e-05	0.000199	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—GBE1—epilepsy syndrome	3.06e-05	0.000198	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—PPP1R3C—epilepsy syndrome	3.06e-05	0.000198	CbGpPWpGaD
Methyldopa—ADRA2A—Platelet activation, signaling and aggregation—ALB—epilepsy syndrome	3.01e-05	0.000194	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—GRM1—epilepsy syndrome	3e-05	0.000194	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—PDYN—epilepsy syndrome	3e-05	0.000194	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—CCR7—epilepsy syndrome	3e-05	0.000194	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—CHRM1—epilepsy syndrome	3e-05	0.000194	CbGpPWpGaD
Methyldopa—ADRA2A—Class A/1 (Rhodopsin-like receptors)—AGT—epilepsy syndrome	2.96e-05	0.000191	CbGpPWpGaD
Methyldopa—DDC—Metabolism—HMOX1—epilepsy syndrome	2.96e-05	0.000191	CbGpPWpGaD
Methyldopa—DDC—Metabolism—CAT—epilepsy syndrome	2.93e-05	0.000189	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—AKT3—epilepsy syndrome	2.89e-05	0.000187	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—CHRM2—epilepsy syndrome	2.89e-05	0.000187	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—BDKRB1—epilepsy syndrome	2.89e-05	0.000187	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—ASAH1—epilepsy syndrome	2.88e-05	0.000186	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—SSTR5—epilepsy syndrome	2.87e-05	0.000185	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—SSTR4—epilepsy syndrome	2.87e-05	0.000185	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—PLAUR—epilepsy syndrome	2.86e-05	0.000185	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR ligand binding—AVP—epilepsy syndrome	2.86e-05	0.000185	CbGpPWpGaD
Methyldopa—DDC—Metabolism—ABCB1—epilepsy syndrome	2.85e-05	0.000184	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—GAL—epilepsy syndrome	2.83e-05	0.000182	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—GABBR1—epilepsy syndrome	2.81e-05	0.000182	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—STXBP1—epilepsy syndrome	2.8e-05	0.000181	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—CHRM3—epilepsy syndrome	2.79e-05	0.00018	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—GRM5—epilepsy syndrome	2.79e-05	0.00018	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—CCR10—epilepsy syndrome	2.75e-05	0.000178	CbGpPWpGaD
Methyldopa—SLC15A1—Transmembrane transport of small molecules—ALB—epilepsy syndrome	2.74e-05	0.000177	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—NT5E—epilepsy syndrome	2.73e-05	0.000176	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—ALAD—epilepsy syndrome	2.73e-05	0.000176	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—HRH3—epilepsy syndrome	2.7e-05	0.000174	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—CX3CR1—epilepsy syndrome	2.68e-05	0.000173	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—OPRM1—epilepsy syndrome	2.66e-05	0.000171	CbGpPWpGaD
Methyldopa—DDC—Metabolism—GPX1—epilepsy syndrome	2.65e-05	0.000171	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—CDC42—epilepsy syndrome	2.64e-05	0.00017	CbGpPWpGaD
Methyldopa—COMT—Metabolism—HMOX1—epilepsy syndrome	2.63e-05	0.00017	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—CX3CL1—epilepsy syndrome	2.63e-05	0.000169	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—CHRM2—epilepsy syndrome	2.63e-05	0.000169	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—BDKRB1—epilepsy syndrome	2.63e-05	0.000169	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—CACNA1A—epilepsy syndrome	2.6e-05	0.000168	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—ALDH7A1—epilepsy syndrome	2.6e-05	0.000168	CbGpPWpGaD
Methyldopa—COMT—Metabolism—CAT—epilepsy syndrome	2.6e-05	0.000168	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—GABBR1—epilepsy syndrome	2.56e-05	0.000165	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—ST3GAL3—epilepsy syndrome	2.55e-05	0.000164	CbGpPWpGaD
Methyldopa—COMT—Metabolism—ABCB1—epilepsy syndrome	2.53e-05	0.000163	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—CCR3—epilepsy syndrome	2.51e-05	0.000162	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—ADSL—epilepsy syndrome	2.5e-05	0.000161	CbGpPWpGaD
Methyldopa—ADRA2A—Class A/1 (Rhodopsin-like receptors)—POMC—epilepsy syndrome	2.5e-05	0.000161	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—HRH3—epilepsy syndrome	2.45e-05	0.000158	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—GLUL—epilepsy syndrome	2.45e-05	0.000158	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—NPY—epilepsy syndrome	2.44e-05	0.000158	CbGpPWpGaD
Methyldopa—ADRA2A—Class A/1 (Rhodopsin-like receptors)—CCL2—epilepsy syndrome	2.44e-05	0.000158	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR ligand binding—CCR5—epilepsy syndrome	2.43e-05	0.000157	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—OPRM1—epilepsy syndrome	2.41e-05	0.000156	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—GRM2—epilepsy syndrome	2.41e-05	0.000155	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—CACNA1D—epilepsy syndrome	2.4e-05	0.000155	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR ligand binding—HTR2A—epilepsy syndrome	2.38e-05	0.000154	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—CRH—epilepsy syndrome	2.36e-05	0.000152	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—OXT—epilepsy syndrome	2.36e-05	0.000152	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—CXCL2—epilepsy syndrome	2.36e-05	0.000152	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—FYN—epilepsy syndrome	2.35e-05	0.000152	CbGpPWpGaD
Methyldopa—COMT—Metabolism—GPX1—epilepsy syndrome	2.35e-05	0.000152	CbGpPWpGaD
Methyldopa—DDC—Metabolism—AGT—epilepsy syndrome	2.32e-05	0.00015	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—CCR3—epilepsy syndrome	2.28e-05	0.000147	CbGpPWpGaD
Methyldopa—DDC—Metabolism—APOE—epilepsy syndrome	2.27e-05	0.000147	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—YWHAZ—epilepsy syndrome	2.26e-05	0.000146	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR ligand binding—AGT—epilepsy syndrome	2.26e-05	0.000146	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—TXNRD1—epilepsy syndrome	2.25e-05	0.000145	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—NPY—epilepsy syndrome	2.22e-05	0.000143	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—AQP1—epilepsy syndrome	2.18e-05	0.000141	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—SSTR3—epilepsy syndrome	2.18e-05	0.000141	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—CXCL2—epilepsy syndrome	2.14e-05	0.000138	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—CRH—epilepsy syndrome	2.14e-05	0.000138	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—OXT—epilepsy syndrome	2.14e-05	0.000138	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—CCL3—epilepsy syndrome	2.14e-05	0.000138	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—CCR2—epilepsy syndrome	2.13e-05	0.000138	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—SST—epilepsy syndrome	2.13e-05	0.000138	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—ST3GAL3—epilepsy syndrome	2.13e-05	0.000138	CbGpPWpGaD
Methyldopa—ADRA2A—Platelet activation, signaling and aggregation—SRC—epilepsy syndrome	2.13e-05	0.000137	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—CCR8—epilepsy syndrome	2.09e-05	0.000135	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—NPY2R—epilepsy syndrome	2.09e-05	0.000135	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—CCR9—epilepsy syndrome	2.09e-05	0.000135	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—SSTR1—epilepsy syndrome	2.09e-05	0.000135	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—ARHGEF9—epilepsy syndrome	2.09e-05	0.000135	CbGpPWpGaD
Methyldopa—ADRA2A—Platelet activation, signaling and aggregation—VEGFA—epilepsy syndrome	2.07e-05	0.000134	CbGpPWpGaD
Methyldopa—COMT—Metabolism—AGT—epilepsy syndrome	2.06e-05	0.000133	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—GRM3—epilepsy syndrome	2.05e-05	0.000132	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—GRM4—epilepsy syndrome	2.05e-05	0.000132	CbGpPWpGaD
Methyldopa—COMT—Metabolism—APOE—epilepsy syndrome	2.02e-05	0.00013	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—SSTR2—epilepsy syndrome	2.01e-05	0.00013	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—DUSP4—epilepsy syndrome	2.01e-05	0.00013	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—PLAU—epilepsy syndrome	2.01e-05	0.000129	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—BDKRB2—epilepsy syndrome	2e-05	0.000129	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—CXCL12—epilepsy syndrome	2e-05	0.000129	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—KCNJ11—epilepsy syndrome	1.97e-05	0.000127	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—CHRM3—epilepsy syndrome	1.97e-05	0.000127	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—CNR1—epilepsy syndrome	1.97e-05	0.000127	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—PLCB1—epilepsy syndrome	1.96e-05	0.000127	CbGpPWpGaD
Methyldopa—DDC—Metabolism—POMC—epilepsy syndrome	1.95e-05	0.000126	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—GRM8—epilepsy syndrome	1.94e-05	0.000125	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—PGF—epilepsy syndrome	1.94e-05	0.000125	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—CCR2—epilepsy syndrome	1.94e-05	0.000125	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—SST—epilepsy syndrome	1.94e-05	0.000125	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—HTR7—epilepsy syndrome	1.92e-05	0.000124	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR ligand binding—POMC—epilepsy syndrome	1.9e-05	0.000123	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—PRKCB—epilepsy syndrome	1.87e-05	0.00012	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR ligand binding—CCL2—epilepsy syndrome	1.86e-05	0.00012	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—GNAO1—epilepsy syndrome	1.85e-05	0.000119	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—OPRD1—epilepsy syndrome	1.85e-05	0.000119	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—NOS2—epilepsy syndrome	1.84e-05	0.000119	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—AKT3—epilepsy syndrome	1.83e-05	0.000118	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—BDKRB2—epilepsy syndrome	1.82e-05	0.000117	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—CXCL12—epilepsy syndrome	1.82e-05	0.000117	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—CNR1—epilepsy syndrome	1.79e-05	0.000115	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—PLCB1—epilepsy syndrome	1.78e-05	0.000115	CbGpPWpGaD
Methyldopa—DDC—Metabolism—ALB—epilepsy syndrome	1.78e-05	0.000115	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—CCR7—epilepsy syndrome	1.78e-05	0.000115	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—PDYN—epilepsy syndrome	1.78e-05	0.000115	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—GRM1—epilepsy syndrome	1.78e-05	0.000115	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—CHRM1—epilepsy syndrome	1.78e-05	0.000115	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—HTR7—epilepsy syndrome	1.74e-05	0.000113	CbGpPWpGaD
Methyldopa—COMT—Metabolism—POMC—epilepsy syndrome	1.73e-05	0.000112	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—HBEGF—epilepsy syndrome	1.69e-05	0.000109	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—CDC42—epilepsy syndrome	1.67e-05	0.000108	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—GAL—epilepsy syndrome	1.67e-05	0.000108	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—GFAP—epilepsy syndrome	1.67e-05	0.000108	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—AKT3—epilepsy syndrome	1.66e-05	0.000107	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—CASP2—epilepsy syndrome	1.65e-05	0.000106	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—GRM5—epilepsy syndrome	1.65e-05	0.000106	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—CHRM3—epilepsy syndrome	1.65e-05	0.000106	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—AVP—epilepsy syndrome	1.62e-05	0.000104	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—ABCG2—epilepsy syndrome	1.61e-05	0.000104	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—CX3CR1—epilepsy syndrome	1.58e-05	0.000102	CbGpPWpGaD
Methyldopa—COMT—Metabolism—ALB—epilepsy syndrome	1.58e-05	0.000102	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—CYP2C19—epilepsy syndrome	1.57e-05	0.000101	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—CYP11A1—epilepsy syndrome	1.56e-05	0.000101	CbGpPWpGaD
Methyldopa—DDC—Metabolism—PTGS2—epilepsy syndrome	1.56e-05	0.0001	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—CX3CL1—epilepsy syndrome	1.55e-05	0.0001	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—BDKRB1—epilepsy syndrome	1.55e-05	0.0001	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—CHRM2—epilepsy syndrome	1.55e-05	0.0001	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—ALB—epilepsy syndrome	1.55e-05	0.0001	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—CDC42—epilepsy syndrome	1.52e-05	9.78e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—GABBR1—epilepsy syndrome	1.51e-05	9.74e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—AVP—epilepsy syndrome	1.47e-05	9.47e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—HRH3—epilepsy syndrome	1.45e-05	9.34e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—OPRM1—epilepsy syndrome	1.42e-05	9.19e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—CYP2D6—epilepsy syndrome	1.41e-05	9.07e-05	CbGpPWpGaD
Methyldopa—COMT—Metabolism—PTGS2—epilepsy syndrome	1.38e-05	8.92e-05	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—CCR5—epilepsy syndrome	1.37e-05	8.87e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—CCR3—epilepsy syndrome	1.35e-05	8.68e-05	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—HTR2A—epilepsy syndrome	1.34e-05	8.68e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—BCHE—epilepsy syndrome	1.33e-05	8.6e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Platelet activation, signaling and aggregation—AKT1—epilepsy syndrome	1.32e-05	8.53e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—NPY—epilepsy syndrome	1.31e-05	8.46e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—ATP2A2—epilepsy syndrome	1.31e-05	8.46e-05	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—AGT—epilepsy syndrome	1.28e-05	8.23e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—SLC2A1—epilepsy syndrome	1.27e-05	8.21e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—HSPB1—epilepsy syndrome	1.26e-05	8.16e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—CCL3—epilepsy syndrome	1.26e-05	8.16e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—CRH—epilepsy syndrome	1.26e-05	8.16e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—OXT—epilepsy syndrome	1.26e-05	8.16e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—CXCL2—epilepsy syndrome	1.26e-05	8.16e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—PLCB1—epilepsy syndrome	1.26e-05	8.12e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—TH—epilepsy syndrome	1.25e-05	8.09e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—CCR5—epilepsy syndrome	1.25e-05	8.05e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—HTR2A—epilepsy syndrome	1.22e-05	7.88e-05	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—PRKCB—epilepsy syndrome	1.18e-05	7.61e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—TSC1—epilepsy syndrome	1.18e-05	7.59e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—PTK2B—epilepsy syndrome	1.18e-05	7.59e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—AGT—epilepsy syndrome	1.16e-05	7.48e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—SST—epilepsy syndrome	1.14e-05	7.38e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—NTRK2—epilepsy syndrome	1.14e-05	7.38e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—CCR2—epilepsy syndrome	1.14e-05	7.38e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—DUSP6—epilepsy syndrome	1.13e-05	7.32e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—PLAT—epilepsy syndrome	1.11e-05	7.19e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—SRC—epilepsy syndrome	1.1e-05	7.07e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—CXCL12—epilepsy syndrome	1.08e-05	6.94e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—BDKRB2—epilepsy syndrome	1.08e-05	6.94e-05	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—POMC—epilepsy syndrome	1.07e-05	6.93e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—PRKCB—epilepsy syndrome	1.07e-05	6.91e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—VEGFA—epilepsy syndrome	1.07e-05	6.89e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—IL6ST—epilepsy syndrome	1.07e-05	6.88e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—JUNB—epilepsy syndrome	1.06e-05	6.81e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—CNR1—epilepsy syndrome	1.06e-05	6.81e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—PLCB1—epilepsy syndrome	1.05e-05	6.79e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—HMOX1—epilepsy syndrome	1.05e-05	6.75e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—CAT—epilepsy syndrome	1.03e-05	6.66e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—HTR7—epilepsy syndrome	1.03e-05	6.65e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—ABCB1—epilepsy syndrome	1e-05	6.48e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—HBEGF—epilepsy syndrome	1e-05	6.45e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—AKT3—epilepsy syndrome	9.81e-06	6.33e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—POMC—epilepsy syndrome	9.75e-06	6.29e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—ADAM10—epilepsy syndrome	9.59e-06	6.19e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—CCL2—epilepsy syndrome	9.54e-06	6.16e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—GPX1—epilepsy syndrome	9.33e-06	6.02e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—S100B—epilepsy syndrome	9.06e-06	5.85e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—SOCS3—epilepsy syndrome	8.98e-06	5.79e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—CDC42—epilepsy syndrome	8.95e-06	5.78e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—AVP—epilepsy syndrome	8.67e-06	5.59e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—HES1—epilepsy syndrome	8.2e-06	5.29e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—AGT—epilepsy syndrome	8.19e-06	5.28e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—APOE—epilepsy syndrome	8.02e-06	5.18e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—FYN—epilepsy syndrome	7.97e-06	5.14e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—H2AFX—epilepsy syndrome	7.94e-06	5.13e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—MEF2C—epilepsy syndrome	7.93e-06	5.12e-05	CbGpPWpGaD
Methyldopa—DDC—Metabolism—AKT1—epilepsy syndrome	7.83e-06	5.05e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—YWHAZ—epilepsy syndrome	7.66e-06	4.94e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—NGF—epilepsy syndrome	7.58e-06	4.89e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—CCR5—epilepsy syndrome	7.37e-06	4.76e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—HTR2A—epilepsy syndrome	7.21e-06	4.65e-05	CbGpPWpGaD
Methyldopa—COMT—Metabolism—AKT1—epilepsy syndrome	6.95e-06	4.48e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—POMC—epilepsy syndrome	6.89e-06	4.45e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—TSC2—epilepsy syndrome	6.85e-06	4.42e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—AGT—epilepsy syndrome	6.84e-06	4.42e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—AKT1—epilepsy syndrome	6.81e-06	4.4e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—APOE—epilepsy syndrome	6.71e-06	4.33e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—KDR—epilepsy syndrome	6.57e-06	4.24e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—PRKCB—epilepsy syndrome	6.32e-06	4.08e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—IL6ST—epilepsy syndrome	6.3e-06	4.06e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—ALB—epilepsy syndrome	6.28e-06	4.05e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—POMC—epilepsy syndrome	5.76e-06	3.72e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—CCL2—epilepsy syndrome	5.64e-06	3.64e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—PTGS2—epilepsy syndrome	5.5e-06	3.55e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—FGF2—epilepsy syndrome	5.09e-06	3.29e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—RELA—epilepsy syndrome	4.73e-06	3.05e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—MTOR—epilepsy syndrome	4.64e-06	2.99e-05	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—AKT1—epilepsy syndrome	4.31e-06	2.78e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—CASP3—epilepsy syndrome	4.27e-06	2.75e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—JUN—epilepsy syndrome	4.14e-06	2.67e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—MMP9—epilepsy syndrome	4.03e-06	2.6e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—AKT1—epilepsy syndrome	3.91e-06	2.52e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—SRC—epilepsy syndrome	3.72e-06	2.4e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—VEGFA—epilepsy syndrome	3.62e-06	2.34e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—AKT1—epilepsy syndrome	2.76e-06	1.78e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—AKT1—epilepsy syndrome	2.31e-06	1.49e-05	CbGpPWpGaD
